BCL2 and acute myeloid leukemia: However, the treatment landscape for AML has changed substantially in the past 5 years with the emergence of new molecularly targeted drugs, including venetoclax to target BCL2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant IDH1/2 (DiNardo & Wei, 2020).